proANP as a marker for heart failure could be missed with a nonfasting sample. If the clinical presentation is unclear, such an occurrence could have dire consequences for the patient with values that are otherwise in the diagnostically "gray zone." For now, the recommendation is that proANP measurements be made on fasting patients. Future studies must also examine the effects of meal intake on the active hormones (ANP and BNP), for which their profiles with respect to food intake are completely unknown. Finally, investigations for mechanistic insights into this phenomenon should address the possible relationship between insulin and natriuretic peptide secretion to explain the current finding and perhaps the reportedly low plasma proANP and proBNP concentrations in obese persons.
In conclusion, plasma proANP concentrations, but not proBNP concentrations, are affected by meal intake, with a decrease of 50% after 2 h. This observation needs to be confirmed in clinical studies of proANP. If the results are confirmed, the findings may provide new biological insight into insulinresistant persons or patients with diabetes. 
Comparison of BleomycinDetectable Iron and Labile Plasma Iron Assays

To the Editor:
Non-transferrin-bound iron (NTBI) 1 is detected in the plasma of patients with diseases in which the transferrin-binding capacity for iron is exceeded by a massive iron overload, such as in certain forms of thalassemia and hemochromatosis, repeated blood transfusions, or bone marrow failure. NTBI may occur in plasma as insoluble polynuclear ferrihydrate species, as Fe(III) citrate or acetate complexes, or bound to certain flavonoids, amino acids, albumin, or modified albumin. Excess iron is harmful because it causes oxidative stress, accumulates in and damages tissues, and enhances the growth of pathogens. Therefore, the measurement of NTBI is of clinical importance, because NTBI may be used as an indicator of systemic iron overload and iron toxicity (1, 2 ) .
We compared 2 NTBI assays: a labile plasma iron (LPI) assay that uses desferrioxamine as the iron chelator (3 ) and a microwell modification of a bleomycin-detectable iron (BDI) assay (2 ) . The BDI assay is an indirect method based on the formation redox-active complexes between NTBI in the sample and the bleomycin reagent. The Fe(II)-bleomycin complex then degrades DNA in the sample mixture via a free-radical reaction, which can be measured photometrically. The detection limit of our BDI assay was 0.05 mol/L, and the interassay CV was 18% and 9.8% at 0.2 mol/L and 1.5 mol/L, respectively (2 ). The LPI assay is based on the measurement of the redox-active and readily chelatable fraction of serum NTBI. The assay measures iron-catalyzed radical generation in the presence of a low ascorbate concentration. Radical generation is measured with the fluorogenic redoxsensitive probe dihydrorhodamine 123 (Sigma-Aldrich), and ironcatalyzed radical generation is calculated by subtracting the radical generation in the presence of 100 mol/L of the iron chelator desferrioxamine (Novartis International) (3 ). In our laboratory, the detection limit of this assay was 0.07 mol/L, which is calculated as 3 SDs above the mean of a zero sample (n ϭ 8). The interassay CV was 11% and 12% at 0.3 mol/L (n ϭ 8) and 2.1 mol/L (n ϭ 8), respectively. The transferrin concentration was measured, and the percentage of transferrin saturation (TS) was calculated as previously described (2 ).
We measured NTBI and TS in 78 serum samples from 5 leukemia patients undergoing allogeneic hematopoietic stem cell transplantation, as described in a previous report (4 ) . The median serum NTBI concentration was 0.12 g/L (95% CI, 0.06 -0.21 g/L) and 0.10 g/L (95% CI, 0.05-0.16 g/L) as measured with the BDI and LPI assays, respectively. The results were correlated according to the equation: y ϭ 1.33x Ϫ 0.06 g/L, where x and y are the NTBI concentrations obtained with the BDI and LPI assays, respectively (S y͉x ϭ 0.17, Deming regression). There was no statistically significant difference between the NTBI results obtained by the 2 methods (P ϭ 0.329, paired t-test). The median TS in the samples was 89.9% (95% CI, 83.1%-92.4%). The NTBI concentration measured by both methods was correlated with TS (P Յ 0.0001). The NTBI concentrations in samples with TS Ͻ87% were low: For the BDI assay, all NTBI results except one (NTBI, 0.21 g/L; TS, 13.6%) were Ͻ0.1 mol/L. For the LPI assay, all NTBI results were Ͻ0.17 mol/L (Fig. 1) .
The exact biochemical nature of NTBI is unknown, and analytical approaches to measure NTBI vary with respect to testing principle and practical application. In 2005, an international roundrobin for the quantification of serum NTBI compared 8 methods in 6 different laboratories (5 ) . Seven of the methods were chelating assays based on 5 different chelators, and one was our BDI assay (2 ) . The methods differed considerably in their NTBI results, and the BDI assay measured the lowest NTBI concentrations (5 ). The mobilization of NTBI by chelators from complexes in which NTBI is not available for the bleomycin reagent may explain this discrepancy. The LPI and BDI methods produced concordant results in the present study, suggesting that both methods measure the same form of NBTI in plasma (r ϭ 0.87).
We compared NTBI assays with serum samples from patients undergoing stem cell transplantation for hematologic malignancies (2 ) . Therapies related to iron chelation are of special interest for this patient group. Avoiding NTBI formation is also an important therapeutic goal in other diseases in which NTBI has been observed, i.e., hemochromatosis, hepcidin or ferroportin deficiency, ␤-thalassemia, liver diseases, endstage renal disease, diabetes, and myelodysplastic syndrome (1 ). The LPI assay detects the redoxactive NTBI, i.e., the potentially toxic species of plasma NTBI, and may therefore be more relevant for clinical use than the BDI assay. For the Liaison assay, the 2 scenarios yielded similar coefficients of determination; however, these values were different for all of the other assays. The regression slopes and r 2 values of the Architect and Cobas assays both de-
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